摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2,3-Dicchlor-5-ethyl-thiophen, '2-Ethyl-4,5-dichlor-thiophen | 89380-35-8

中文名称
——
中文别名
——
英文名称
2,3-Dicchlor-5-ethyl-thiophen, '2-Ethyl-4,5-dichlor-thiophen
英文别名
2-Ethyl-4,5-dichlor-thiophen;2,3-dichloro-5-ethyl-thiophene;2-ethyl-4,5-dichloro-thiophene;2-Aethyl-4,5-dichlor-thiophen;2,3-Dichloro-5-ethylthiophene
2,3-Dicchlor-5-ethyl-thiophen, '2-Ethyl-4,5-dichlor-thiophen化学式
CAS
89380-35-8
化学式
C6H6Cl2S
mdl
——
分子量
181.086
InChiKey
WLAABMWDRZNBLC-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4
  • 重原子数:
    9
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.33
  • 拓扑面积:
    28.2
  • 氢给体数:
    0
  • 氢受体数:
    1

文献信息

  • SUBSTITUTED SULPHONAMIDES FOR CONTROLLING ANIMAL PESTS
    申请人:BAYER CROPSCIENCE AKTIENGESELLSCHAFT
    公开号:US20200288710A1
    公开(公告)日:2020-09-17
    The present invention relates to the use of a compound of the general formula (I) in which M and D have the meanings given in the description for controlling animal pests.
    本发明涉及使用一种通式(I)中的化合物,其中M和D的含义如描述中所示,用于控制动物害虫。
  • QUINOLINYL AND BENZOTHIAZOLYL MODULATORS
    申请人:McGee Lawrence R.
    公开号:US20090221635A1
    公开(公告)日:2009-09-03
    Compounds, compositions and methods are provided that are useful in the treatment or prevention of a condition or disorder mediated by PPARγ. In particular, the compounds of the invention modulate the function of PPARγ. The subject methods are particularly useful in the treatment and/or prevention of diabetes, obesity, hypercholesterolemia, rheumatoid arthritis and atherosclerosis.
    本发明提供了一些化合物、组合物和方法,它们对于治疗或预防由PPARγ介导的疾病或疾病非常有用。特别地,本发明的化合物调节PPARγ的功能。该方法特别适用于治疗和/或预防糖尿病、肥胖症、高胆固醇血症、类风湿性关节炎和动脉粥样硬化。
  • PROTEASOME INHIBITORS HAVING CHYMOTRYPSIN-LIKE ACTIVITY
    申请人:Lawrence Harshani
    公开号:US20120142917A1
    公开(公告)日:2012-06-07
    Disclosed herein is the use of HLM-008182, as well as its analogues formed via in-house synthesis, as a potent proteasome inhibitors. A new method was developed for HLM-008182 through a four-step protocol and the method was further optimized to a two step protocol. The synthesis in both protocols was regioselective with TiCl 4 . The reaction was highly efficient with microwave assisted heating and THF as solvent. The modification around the molecule HLM-008182 established primary SAR, indicating that the proteasome inhibition activity was a function of the 2-side chain.
    本文披露了使用HLM-008182及其由内部合成形成的类似物作为有效的蛋白酶抑制剂。通过四步协议开发了HLM-008182的新方法,并将该方法进一步优化为两步协议。在两种协议的合成中,都使用了TiCl4进行区域选择性反应。微波辅助加热和THF作为溶剂使反应高效。对HLM-008182分子周围的修饰建立了主要的SAR,表明蛋白酶体抑制活性是2侧链的一个功能。
  • PROTEASOME INHIBITORS FOR SELECTIVELY INDUCING APOPTOSIS IN CANCER CELLS
    申请人:Lawrence Harshani
    公开号:US20110201609A1
    公开(公告)日:2011-08-18
    The subject invention concerns compounds having activity as inhibitors of proteasomes and methods of using the subject compounds. In one embodiment, a compound of the invention has the chemical structure shown in formula I: wherein R 1 is an organic cyclic ring structure bonded to a sulfonamide structure; R 2 is H, halogen, alkyl, —NR 6 R 7 , or heteroalkyl; R 3 is H, halogen, —OH, —O-alkyl, alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, —NO 2 , —NH 2 or substituted amines; R 4 is H, alkyl, heteroalkyl, aryl, or heteroaryl, any of which can be optionally substituted with one or more of —NO 2 , alkyl, heteroalkyl, aryl, or heteroaryl, or halogen; R 5 is H, —OH, halogen, alkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, —O-alkyl, —O-aryl, heteroalkyl, —NO 2 , —NH 2 , or substituted amine; and R 6 and R 7 are independently H, O, alkyl, aryl, heterocycloalkyl, or heteroaryl, or together can form a heterocycloalkyl or a heteroaryl, any of which can be optionally substituted with one or more of —NO 2 , alkyl, heteroalkyl, aryl, or halogen; or a pharmaceutically acceptable salt or hydrate thereof. In another embodiment, a compound of the invention has the chemical structure shown in formula II: wherein Q, W, X, Y, Z are each independently carbon, oxygen, or nitrogen; R 1 is H, or X 1 R 8 ; R 2 is heteroalkyl, which can be optionally substituted with one or more of —OH, halogen, —C(O)OR 4 , alkyl, heteroalkyl, heterocycloalkyl, or heteroaryl; R 3 is heterocycloalkyl, aryl, heteroaryl, any of which can be optionally substituted with one or more of a halogen or —OH; and R 4 is H or alkyl; R 5 is halogen, alkyl or nitro; R 6 is nitro, X 2 R 9 or a halogen; R 7 is H or alkyl; R 8 is H, alkyl, aryl, CH 2 -alkyl-aryl, -alkyl-C(O)OH, or alkyl-tetrazole (aromatic and aliphatic heterocyclic groups); R 9 is H or alkyl; X 1 is oxygen, nitrogen, or sulfur; X 2 is oxygen, nitrogen, or sulfur; or a pharmaceutically acceptable salt or hydrate thereof.
    本发明涉及作为蛋白酶抑制剂的化合物及使用该化合物的方法。在一种实施方式中,本发明的化合物具有公式I所示的化学结构:其中,R1是与磺酰胺结构键合的有机环状环结构;R2是H、卤素、烷基、-NR6R7或杂环烷基;R3是H、卤素、-OH、-O-烷基、烷基、环烷基、杂环烷基、芳基、杂芳基、-NO2、-NH2或取代胺;R4是H、烷基、杂烷基、芳基或杂芳基,其中任何一个都可以选择性地取代一个或多个- 、烷基、杂烷基、芳基或杂芳基或卤素;R5是H、-OH、卤素、烷基、芳基、杂芳基、环烷基、杂环烷基、-O-烷基、-O-芳基、杂烷基、- 、-NH2或取代胺;R6和R7分别是H、O、烷基、芳基、杂环烷基或杂芳基,或者一起形成杂环烷基或杂芳基,其中任何一个都可以选择性地取代一个或多个- 、烷基、杂烷基、芳基或卤素;或其药学上可接受的盐或合物。在另一种实施方式中,本发明的化合物具有公式II所示的化学结构:其中,Q、W、X、Y、Z分别独立地是碳、氧或氮;R1是H或X1R8;R2是杂环烷基,可以选择性地取代一个或多个-OH、卤素、-C(O)OR4、烷基、杂烷基、杂环烷基或杂芳基;R3是杂环烷基、芳基、杂芳基,其中任何一个都可以选择性地取代一个或多个卤素或-OH;R4是H或烷基;R5是卤素、烷基或硝基;R6是硝基、X2R9或卤素;R7是H或烷基;R8是H、烷基、芳基、CH2-烷基-芳基、-烷基-C(O)OH或烷基-四唑(芳香和脂肪族杂环基);R9是H或烷基;X1是氧、氮或;X2是氧、氮或;或其药学上可接受的盐或合物。
  • SUBSTITUIERTE SULFONYLAMIDE ZUR BEKÄMPFUNG TIERISCHER SCHÄDLINGE
    申请人:Bayer Aktiengesellschaft
    公开号:EP3534709B1
    公开(公告)日:2021-06-16
查看更多

同类化合物

()-2-(5-甲基-2-氧代苯并呋喃-3(2)-亚乙基)乙酸乙酯 (双(2,2,2-三氯乙基)) (乙基N-(1H-吲唑-3-基羰基)ethanehydrazonoate) (Z)-3-[[[2,4-二甲基-3-(乙氧羰基)吡咯-5-基]亚甲基]吲哚-2--2- (S)-(-)-5'-苄氧基苯基卡维地洛 (S)-(-)-2-(α-(叔丁基)甲胺)-1H-苯并咪唑 (S)-(-)-2-(α-甲基甲胺)-1H-苯并咪唑 (S)-氨氯地平-d4 (S)-8-氟苯并二氢吡喃-4-胺 (S)-4-(叔丁基)-2-(喹啉-2-基)-4,5-二氢噁唑 (S)-4-氯-1,2-环氧丁烷 (S)-3-(2-(二氟甲基)吡啶-4-基)-7-氟-3-(3-(嘧啶-5-基)苯基)-3H-异吲哚-1-胺 (S)-2-(环丁基氨基)-N-(3-(3,4-二氢异喹啉-2(1H)-基)-2-羟丙基)异烟酰胺 (SP-4-1)-二氯双(喹啉)-钯 (SP-4-1)-二氯双(1-苯基-1H-咪唑-κN3)-钯 (R,S)-可替宁N-氧化物-甲基-d3 (R,S)-六氢-3H-1,2,3-苯并噻唑-2,2-二氧化物-3-羧酸叔丁酯 (R)-(+)-5'-苄氧基卡维地洛 (R)-(+)-2,2'',6,6''-四甲氧基-4,4''-双(二苯基膦基)-3,3''-联吡啶(1,5-环辛二烯)铑(I)四氟硼酸盐 (R)-卡洛芬 (R)-N'-亚硝基尼古丁 (R)-DRF053二盐酸盐 (R)-4-异丙基-2-恶唑烷硫酮 (R)-3-甲基哌啶盐酸盐; (R)-2-苄基哌啶-1-羧酸叔丁酯 (N-(Boc)-2-吲哚基)二甲基硅烷醇钠 (N-{4-[(6-溴-2-氧代-1,3-苯并恶唑-3(2H)-基)磺酰基]苯基}乙酰胺) (E)-2-氰基-3-(5-(2-辛基-7-(4-(对甲苯基)-1,2,3,3a,4,8b-六氢环戊[b]吲哚-7-基)-2H-苯并[d][1,2,3]三唑-4-基)噻吩-2-基)丙烯酸 (E)-2-氰基-3-[5-(2,5-二氯苯基)呋喃-2-基]-N-喹啉-8-基丙-2-烯酰胺 (8α,9S)-(+)-9-氨基-七氢呋喃-6''-醇,值90% (6R,7R)-7-苯基乙酰胺基-3-[(Z)-2-(4-甲基噻唑-5-基)乙烯基]-3-头孢唑啉-4-羧酸二苯甲基酯 (6-羟基嘧啶-4-基)乙酸 (6,7-二甲氧基-4-(3,4,5-三甲氧基苯基)喹啉) (6,6-二甲基-3-(甲硫基)-1,6-二氢-1,2,4-三嗪-5(2H)-硫酮) (5aS,6R,9S,9aR)-5a,6,7,8,9,9a-六氢-6,11,11-三甲基-2-(2,3,4,5,6-五氟苯基)-6,9-甲基-4H-[1,2,4]三唑[3,4-c][1,4]苯并恶嗪四氟硼酸酯 (5R,Z)-3-(羟基((1R,2S,6S,8aS)-1,3,6-三甲基-2-((E)-prop-1-en-1-yl)-1,2,4a,5,6,7,8,8a-八氢萘-1-基)亚甲基)-5-(羟甲基)-1-甲基吡咯烷-2,4-二酮 (5E)-5-[(2,5-二甲基-1-吡啶-3-基-吡咯-3-基)亚甲基]-2-亚磺酰基-1,3-噻唑烷-4-酮 (5-(4-乙氧基-3-甲基苄基)-1,3-苯并二恶茂) (5-溴-3-吡啶基)[4-(1-吡咯烷基)-1-哌啶基]甲酮 (5-氯-2,1,3-苯并噻二唑-4-基)-氨基甲氨基硫代甲酸甲酯一氢碘 (5-氨基-6-氰基-7-甲基[1,2]噻唑并[4,5-b]吡啶-3-甲酰胺) (5-氨基-1,3,4-噻二唑-2-基)甲醇 (4aS-反式)-八氢-1H-吡咯并[3,4-b]吡啶 (4aS,9bR)-6-溴-2,3,4,4a,5,9b-六氢-1H-吡啶并[4,3-B]吲哚 (4S,4''S)-2,2''-环亚丙基双[4-叔丁基-4,5-二氢恶唑] (4-(4-氯苯基)硫代)-10-甲基-7H-benzimidazo(2,1-A)奔驰(德)isoquinolin-7一 (4-苄基-2-甲基-4-nitrodecahydropyrido〔1,2-a][1,4]二氮杂) (4-甲基环戊-1-烯-1-基)(吗啉-4-基)甲酮 (4-己基-2-甲基-4-nitrodecahydropyrido〔1,2-a][1,4]二氮杂) (4,5-二甲氧基-1,2,3,6-四氢哒嗪)